Results 51 to 60 of about 8,517,970 (127)

Reacción similar a la enfermedad del suero secundaria al uso de cefalotina: reporte de un caso

Infectio, 2022
Serum sickness (SS) and SS-like reactions (SSLR) are indistinguishable clinical entities but with different pathophysiological processes, particularly regarding its impact on the complement system.
Germán Sepúlveda-Barbosa
doaj   +1 more source

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh, Joseph Mitchell, Cecilia Stålsby Lundborg, Megha Sharma   +3 more
wiley   +1 more source

Safety Profile and Signal Detection of Oxazolidinone Antibiotics Using WHO-VigiAccess Database

Bali Medical Journal
Objective: Oxazolidinone antibiotics are mainly used for skin and soft tissue infections,sepsis,bone marrow inflammation and other diseases caused by Gram-positive bacteria. Despite the emergence of oxazolidinones as a preferred treatment for drug-resistant Gram-positive bacterial infections, there remains a scarcity of large-scale, real-world studies ...
Renzhu Liu, Qichang Xing, Zheng Liu, Wencan Li, Qingzi Yan, Keqian Chen, Xiang Liu   +6 more
openaire   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Integrating gepants into clinical practice for the acute treatment of migraine

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 976-989, April 2026.
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Richard B. Lipton, David W. Dodick, Linda Davis, Stephanie J. Nahas, Peter J. Goadsby   +4 more
wiley   +1 more source

Case Report: Omadacycline in the Treatment of Community‐Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies

Clinical Case Reports, Volume 13, Issue 12, December 2025.
ABSTRACT Omadacycline, a novel once‐daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community‐acquired pneumonia (CAP) in adults. However, the safety and efficacy of omadacycline in younger children have not yet been established.
Ziqi Xu, Wen Pan, Hui Lei, Chen Dong, Biao Zou, Sainan Shu, Wenting Zhang   +6 more
wiley   +1 more source

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper

Allergy, Volume 80, Issue 11, Page 2973-2987, November 2025.
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini, Alla Nakonechna, Annick Barbaud, Sevim Bavbek, Gianfranco Calogiuri, Inmaculada Doña, Violeta Kvedariene, Jose Julio Laguna Martinez, Serena Liberati, Mauro Pagani, Antonino Romano   +10 more
wiley   +1 more source

Serious Adverse Events: A Replicability and Validation Study of Naranjo Causality Assessment Tool in a Canadian Clinical Setting

Journal of Evaluation in Clinical Practice, Volume 31, Issue 3, April 2025.
ABSTRACT Rationale Patient safety has become a major concern in healthcare today as 5%–10% of patients experience serious adverse events (SAE) during their hospital stay. The causal assessment of SAE is the responsibility of healthcare professionals (HCP), who use their judgment or a standardize tool. Whether those two methods are replicable to provide
Pallavi Pradhan, Sonia Corbin, Shweta Todkar, Maude Lavallée, Isabelle Cloutier, Rosalie Darveau, Julie Méthot, Anick Bérard, Marie‐Eve Piché, Jacinthe Leclerc   +9 more
wiley   +1 more source

The Real‐World Analysis of Adverse Events With Two Types of Single‐Inhaler Triple Therapy: A VigiAccess Database Study

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
Background The advent of single‐inhaler triple therapies (SITTs), including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), has expanded treatment options for chronic obstructive pulmonary disease (COPD).
Baiquan Zhang, Jiayu Bai, Lu Zhou, Hongda Liu   +3 more
wiley   +1 more source

Sintilimab Pharmacovigilance in Real-World Practice: Analysis Utilizing the WHO VigiAccess Database

Abstract Sintilimab, a high-affinity PD-1 inhibitor, blocks the interaction between PD-1 and PD-L1 to restore T-cell function. Clinically used with chemotherapy for cancers like non-small cell lung carcinoma and hepatocellular carcinoma, its adverse event (AE) profile remains critical. Here we conducted the pharmacovigilance analysis of
Youjia Guo, Li Wen, Fangcheng Jiang, Liling Pan, Lei He, Zhaoji Liu, Qiong Wu, Zefeng Lai, Qichun Huang, Yan Li   +9 more
openaire   +1 more source